Symbols / PLYX Stock $3.38 +10.46% Polaryx Therapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
PLYX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Alex Yang J.D., L.L.M.
Exch · Country NCM · United States
Market Cap 160.02M
Enterprise Value 156.94M
Income -6.48M
Sales —
FCF (ttm) 2.45M
Book/sh 0.10
Cash/sh 0.07
Employees 2
Insider 10d —
IPO Feb 02, 2026
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E —
PEG —
P/S —
P/B 35.21
P/C —
EV/EBITDA —
EV/Sales —
Quick Ratio 3.04
Current Ratio 3.45
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -0.14
EPS next Y —
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-15
Earnings (prior) 2026-05-15
ROA -74.42%
ROE -192.17%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 47.34M
Shs Float 4.98M
Insider Own 73.01%
Instit Own 8.31%
Short Float 1.40%
Short Ratio 1.32
Short Interest 266.65K
52W High 48.91
vs 52W High -93.09%
52W Low 2.20
vs 52W Low 53.64%
Beta —
Impl. Vol. —
Rel Volume 0.19
Avg Volume 914.77K
Volume 169.80K
Target (mean) $10.00
Tgt Median $10.00
Tgt Low $10.00
Tgt High $10.00
# Analysts 1
Recom None
Prev Close $3.06
Price $3.38
Change 10.46%
About

Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$10.00
Mean price target
2. Current target
$3.38
Latest analyst target
3. DCF / Fair value
$0.93
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.38
Low
$10.00
High
$10.00
Mean
$10.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-02-27 init Maxim Group — → Buy $10
News
RSS: Latest PLYX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-18 LANDIS G MICHAEL Chief Financial Officer — 2,867 $2.79 $7,991
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Total Revenue
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
Operating Expense
7.82
+79.71%
4.35
+15.10%
3.78
Research And Development
6.27
+122.91%
2.81
+1.44%
2.77
Selling General And Administration
1.55
+0.91%
1.54
+52.57%
1.01
General And Administrative Expense
1.55
+0.91%
1.54
+52.57%
1.01
Other Gand A
1.55
+0.91%
1.54
+52.57%
1.01
Total Expenses
7.82
+79.71%
4.35
+15.10%
3.78
Operating Income
-7.82
-79.71%
-4.35
-15.10%
-3.78
Total Operating Income As Reported
-7.82
-79.71%
-4.35
-15.10%
-3.78
EBITDA
-7.82
-79.71%
-4.35
-15.10%
-3.78
Normalized EBITDA
-6.66
-52.96%
-4.35
-15.10%
-3.78
EBIT
-7.82
-79.71%
-4.35
-15.10%
-3.78
Total Unusual Items
-1.16
0.00
—
Total Unusual Items Excluding Goodwill
-1.16
0.00
—
Special Income Charges
-1.16
0.00
—
Other Special Charges
1.16
—
—
Net Income
-8.98
+70.40%
-30.36
-703.28%
-3.78
Pretax Income
-8.98
+70.40%
-30.36
-703.28%
-3.78
Other Income Expense
-1.16
+95.52%
-26.00
-1300300.00%
0.00
Other Non Operating Income Expenses
—
-26.00
-1300300.00%
0.00
Tax Rate For Calcs
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-8.98
+70.40%
-30.36
-703.28%
-3.78
Net Income From Continuing Operation Net Minority Interest
-8.98
+70.40%
-30.36
-703.28%
-3.78
Net Income From Continuing And Discontinued Operation
-8.98
+70.40%
-30.36
-703.28%
-3.78
Net Income Continuous Operations
-8.98
+70.40%
-30.36
-703.28%
-3.78
Normalized Income
-7.82
+74.24%
-30.36
-703.28%
-3.78
Net Income Common Stockholders
-8.98
+70.40%
-30.36
-703.28%
-3.78
Diluted EPS
—
-0.64
-703.28%
-0.08
Basic EPS
—
-0.64
-703.28%
-0.08
Basic Average Shares
—
47.34
+0.00%
47.34
Diluted Average Shares
—
47.34
+0.00%
47.34
Diluted NI Availto Com Stockholders
-8.98
+70.40%
-30.36
-703.28%
-3.78
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Total Assets
5.17
+3.38%
5.00
+116.03%
2.31
Current Assets
5.17
+3.38%
5.00
+116.03%
2.31
Cash Cash Equivalents And Short Term Investments
5.14
+11.30%
4.62
+230950.00%
0.00
Cash And Cash Equivalents
5.14
+11.30%
4.62
+230950.00%
0.00
Prepaid Assets
0.00
-100.00%
0.38
-83.57%
2.31
Other Current Assets
0.03
—
—
Total Non Current Assets
0.00
0.00
0.00
Total Liabilities Net Minority Interest
0.60
+109.34%
0.29
-72.16%
1.04
Current Liabilities
0.60
+109.34%
0.29
-72.16%
1.04
Payables And Accrued Expenses
0.58
+102.78%
0.29
-68.32%
0.91
Payables
0.56
+177.72%
0.20
-75.46%
0.82
Accounts Payable
0.47
+552.78%
0.07
-84.78%
0.47
Current Accrued Expenses
0.02
-73.26%
0.09
+0.00%
0.09
Pensionand Other Post Retirement Benefit Plans Current
0.02
+2000.00%
0.00
+0.00%
0.00
Current Debt And Capital Lease Obligation
—
—
0.13
Current Debt
—
—
0.13
Other Current Borrowings
—
—
0.13
Total Non Current Liabilities Net Minority Interest
0.00
0.00
0.00
Stockholders Equity
4.57
-3.12%
4.71
+268.99%
1.28
Common Stock Equity
4.57
-3.12%
4.71
+268.99%
1.28
Capital Stock
0.01
+25.00%
0.00
+300.00%
0.00
Common Stock
0.01
+25.00%
0.00
+300.00%
0.00
Preferred Stock
0.00
0.00
0.00
Share Issued
47.34
+0.00%
47.34
+0.00%
47.34
Ordinary Shares Number
47.34
+0.00%
47.34
+0.00%
47.34
Additional Paid In Capital
104.19
+9.27%
95.36
+54.88%
61.57
Retained Earnings
-99.64
-9.91%
-90.65
-50.35%
-60.29
Total Equity Gross Minority Interest
4.57
-3.12%
4.71
+268.99%
1.28
Total Capitalization
4.57
-3.12%
4.71
+268.99%
1.28
Working Capital
4.57
-3.12%
4.71
+268.99%
1.28
Invested Capital
4.57
-3.12%
4.71
+235.37%
1.41
Total Debt
—
—
0.13
Net Debt
—
—
0.13
Net Tangible Assets
4.57
-3.12%
4.71
+268.99%
1.28
Tangible Book Value
4.57
-3.12%
4.71
+268.99%
1.28
Dueto Related Parties Current
0.09
-30.00%
0.13
-62.86%
0.35
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Operating Cash Flow
-3.94
-53.28%
-2.57
-1387.28%
-0.17
Cash Flow From Continuing Operating Activities
-3.94
-53.28%
-2.57
-1387.28%
-0.17
Net Income From Continuing Operations
-8.98
+70.40%
-30.36
-703.28%
-3.78
Other Non Cash Items
—
26.00
—
Stock Based Compensation
4.72
+96.88%
2.40
-25.86%
3.24
Change In Working Capital
0.32
+150.89%
-0.62
-268.29%
0.37
Change In Prepaid Assets
—
0.00
-100.00%
0.07
Change In Payables And Accrued Expense
0.32
+150.89%
-0.62
-311.22%
0.29
Change In Accrued Expense
-0.04
0.00
+100.00%
-0.00
Change In Payable
0.36
+157.81%
-0.62
-308.39%
0.30
Change In Account Payable
0.40
+199.25%
-0.40
-671.15%
-0.05
Financing Cash Flow
4.47
-37.90%
7.19
+5518.75%
0.13
Cash Flow From Continuing Financing Activities
4.47
-37.90%
7.19
+5518.75%
0.13
Net Issuance Payments Of Debt
0.00
+100.00%
-0.13
-200.00%
0.13
Issuance Of Debt
0.00
-100.00%
0.07
-49.22%
0.13
Repayment Of Debt
0.00
+100.00%
-0.19
0.00
Short Term Debt Issuance
0.00
-100.00%
0.07
-49.22%
0.13
Short Term Debt Payments
0.00
+100.00%
-0.19
0.00
Net Short Term Debt Issuance
0.00
+100.00%
-0.13
-200.00%
0.13
Net Common Stock Issuance
4.49
-38.62%
7.32
0.00
Net Other Financing Charges
-0.03
—
—
Changes In Cash
0.52
-88.70%
4.62
+10364.44%
-0.04
Beginning Cash Position
4.62
+230950.00%
0.00
-95.74%
0.05
End Cash Position
5.14
+11.30%
4.62
+230950.00%
0.00
Free Cash Flow
-3.94
-53.28%
-2.57
-1387.28%
-0.17
Common Stock Issuance
4.49
-38.62%
7.32
0.00
Issuance Of Capital Stock
4.49
-38.62%
7.32
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category